Katsuhiro Mabe

Learn More
BACKGROUND In Japan, treatment guidelines are lacking for patients with upper gastrointestinal symptoms. We aimed to compare the efficacy of different drugs for the treatment of uninvestigated upper gastrointestinal symptoms. METHODS This was a randomized, open-label, parallel-group multicenter study. Helicobacter pylori-negative, endoscopically(More)
Introduction Gastric cancer represents the second leading cause of cancer death worldwide, with some 50,000 individuals dying annually from the disease in Japan, where early endoscopic detection of gastric cancer remains the cornerstone that contributes not only to a decrease in mortality from gastric cancer but also to optimization of care, with the use of(More)
In Japan, efforts have been directed toward improving the detection of early gastric cancer by double contrast radiography and endoscopy, since early cancer has a good prognosis, resulting in Japan having the world's best diagnostic system for early gastric cancer. The 5-year survival rate of gastric cancer patients in Japan is much higher than in Western(More)
Helicobacter pylori is a key factor in the development of gastric cancer; indeed, clearance of H. pylori helps prevent gastric cancer. However, the relationship between gastric cancer and the abundance and diversity of H. pylori genotypes in the stomach remains unknown. Here, we present, for the first time, a quantitative analysis of H. pylori genotypes in(More)
BACKGROUND For endoscopic interventions, heparin bridging therapy is recommended in patients who are at high risk from interruption of antithrombotic therapy. Although heparin bridging has been reported to be effective in preventing thrombosis, several reports have raised concerns about increased risk of bleeding. The aim of this study was to clarify(More)
BACKGROUND Proton pump inhibitors (PPIs) are affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. This study compared the effect of two PPIs on early symptom relief in Japanese patients with reflux esophagitis, classified by the CYP2C19 phenotype. METHODS Patients with reflux esophagitis were randomised to treatment with omeprazole 20 mg or(More)
  • 1